Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough
Dateline City:
KENILWORTH, N.J.
Gefapixant (45 mg Twice Daily) Demonstrated Statistically Significant Decrease in 24-hour Coughs Per Hour Compared to Placebo at Week 12 and 24 in Phase 3 Trials
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced top-line efficacy results from two ongoing pivotal Phase 3 trials (COUGH-1 and COUGH-2) evaluating the efficacy and safety of gefapixant (MK-7264), an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough.
Language:
English
Contact:
Media:
Pamela Eisele, (267) 305-3558
Elizabeth Sell, (267) 305-3877
Investor:
Peter Dannenbaum, (908) 740-1037
Michael DeCarbo, (908) 740-1807
Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck